Browsing by Author Long, Georgina

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 147  next >
Issue DateTitleAuthor(s)Citation
201318F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanomaCarlino, Matteo; Haydu, Lauren; Kefford, Richard (Rick); Long, Georgina; Saunders, Catherine; Curtis, C. Martin; Lebowitz, Peter; Menzies, Alexander; Western Clinical School: Medicine (Westmead); Central Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma, European Journal of Cancer, vol.49, 2, 2013,pp 395-402
2014Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinibAnforth, Rachael; Clements, Arthur; Fernandez Penas, Pablo; Kefford, Richard (Rick); Long, Georgina; Nguyen, Bao; Liu, Michael; Uribe, Pablo; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Nepean Clinical School: MedicineAcneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib, The Australasian Journal of Dermatology, vol.55, 4, 2014,pp 250-254
2015Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Pupo, Gulietta; Rizos, Helen; Scolyer, Richard; Thompson, John; Becker, Jurgen C; Berking, Carola; Eroglu, Zeynep; et al, Various; Gogas, Helen; Gutzmer, R.; Johnson, Douglas B; Sucker, Antje; Ye, Fei; Zhao, Shilin; Zimmer, Lisa; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Pathology; Central Clinical School: SurgeryAcquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms, European Journal of Cancer, vol.51, 18, 2015,pp 2792-2799
2014Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapyKefford, Richard (Rick); Long, Georgina; Chodon, Thinle; Dahlman, Kimberly; et al, Various; Guo, Rongqing; Hong, Aayoung; Hugo, Willy; Johnson, Douglas B; Kong, Xiangju; Koya, Richard; Moriceau, Gatien; Shi, Hubing; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreAcquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy, Cancer Discovery, vol.4, 1, 2014,pp 80-93
2016Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaCarlino, Matteo; Fogarty, Gerald; Guminski, Alexander; Hong, Angela; Kefford, Richard (Rick); Liniker, Elizabeth; Lo, Serigne; Long, Georgina; Menzies, Alexander Maxwel; Ramanujam, Sangeetha; Cooper, Adam; Kong, Benjamin; Wang, T. W.; Western Clinical School: Medicine (Westmead); Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Central Clinical School: Melonoma & Skin Cancer Res. Inst.; The George Institute for Global Health; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma, OncoImmunology, vol.5, 9, 2016,pp 1-7
2014Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanomaLong, Georgina; Bowyer, Samantha; Hicks, Rodney J; Lyle, Megan; McArthur, Grant A.; Millward, Michael; Raleigh, Jeanette; Rao, Aparna; Sandhu, Shahneen; Central Clinical School: The Sydney Cancer CentreActivity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma, Melanoma Research, vol.24, 5, 2014,pp 504-508
2017Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaKefford, Richard (Rick); Long, Georgina; Atkinson, Victoria; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Hauschild, Axel; Haydon, Andrew; Larkin, J; MandalĂ , Mario; Nyakas, Marta; Santinami, Mario; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineAdjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1813-1823
2017Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dalle, S; Del Vecchio, M; et al, Various; Gogas, Helen; Mandala, Mario; Schenker, Michael; Weber, Jeffrey; Northern Clinical School: MedicineAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1824-1835
2017Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative studyLong, Georgina; Menzies, Alexander Maxwel; Chin, Melvin; Harris-Wai, J.; Kasparian, Nadine A; Kaur, R.; Lewis, C; Liang, R.; Meiser, B.; Smith, Sian; Ward, R; Northern Clinical School: Medicine; Northern Clinical School: MedicineAdvanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study, European Journal of Cancer Care, vol.26, 6, 2017,pp 1-11
2017Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabCarlino, Matteo; Guminski, Alexander; Long, Georgina; Menzies, Alexander Maxwel; Park, John; Ramanujam, Sangeetha; Atkinson, V; Eroglu, Z; et al, Various; Johnson, Douglas B; Klein, O; McQuade, J; Shoushtari, A; Tsai, K. K.; Wong, Annie; Western Clinical School: Medicine (Westmead); Northern Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Annals of Oncology, vol.28, 2, 2017,pp 368-376
2013Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in MelanomaBecker, Therese; Carlino, Matteo; Gowrishankar, Kavitha; Kefford, Richard (Rick); Long, Georgina; Pupo, Gulietta; Rizos, Helen; Saw, Robyn; Snoyman, Stephanie; Saunders, Catherine; Zhang, Xu Dong; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: Surgery; Western Clinical School: Westmead Millennium InstituteAntiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma, Molecular Cancer Therapeutics, vol.12, 7, 2013,pp 1332-1342
2012Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionLong, Georgina; Busam, Klaus; Carvajal, Richard; Dummer, R; Egberts, Friederike; Goldinger, Simone; Hauschild, A; Hillen, Uwe; Kashani-Sabet, Mohammed; Lacouture, Mario; Livingstone, Elisabeth; McArthur, Grant A.; Schadendorf, Dirk; Scherag, Andre; Sucker, Antje; Zimmer, Lisa; Central Clinical School: The Sydney Cancer CentreAtypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition, Journal of Clinical Oncology, vol.30, 19, 2012,pp 2375-2383
2017Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialLong, Georgina; Arance, A; Ascierto, Paolo A; Del Vecchio, M; Di Giacomo, A; Dummer, R; Dutriaux, Caroline; et al, Various; Gutzmer, R.; Rutkowski, Piotr; Schadendorf, D; Northern Clinical School: MedicineBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 4, 2017,pp 435-445
2017Biomarker accessible and chemically addressable mechanistic subtypes of braf melanomaLong, Georgina; Rizos, Helen; Ding, Ming; Eskiocak, Banu; et al, Various; Garcia-Rodriguez, Jose; Humphries, Caroline G.; Kollipara, Rahul K.; McMillan, Elizabeth A.; Mendiratta, Saurabh; Wang, Changguang; Zhang, Hailei; Northern Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical ResBiomarker accessible and chemically addressable mechanistic subtypes of braf melanoma, Cancer Discovery, vol.7, 8, 2017,pp 832-851
2015BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell VolumeLong, Georgina; Scolyer, Richard; Bosenberg, Marcus; Held, Matthew; Marzuka-Alcala, Alexander; Meeth, Katrina M; Micevic, Goran; Stern, David F; Theodosakis, Nicholas; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyBRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume, Molecular Cancer Therapeutics, vol.14, 7, 2015,pp 1680-1692
2013BRAF inhibitor activity in V600R metastatic melanomaClements, Arthur; Kefford, Richard (Rick); Long, Georgina; O'Toole, Sandra; Klein, Oliver; Menzies, Alexander; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyBRAF inhibitor activity in V600R metastatic melanoma, European Journal of Cancer, vol.49, 5, 2013,pp 1073-1079
2014BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impactBecker, Therese; Boyd, Suzanah; Carlino, Matteo; Fung, Carina; Haydu, Lauren; Howle, Julie; Kefford, Richard (Rick); Long, Georgina; Mijatov, Branka; Pupo, Gulietta; Rizos, Helen; Saw, Robyn; Scolyer, Richard; Thompson, John; Hyman, Jessica; Menzies, Alexander; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Infectious Diseases; Central Clinical School: Surgery; Western Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: SurgeryBRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact, Clinical Cancer Research, vol.20, 7, 2014,pp 1965-1977
2016BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reportingCooper, Wendy Anne; Kakavand, Hojabr; Long, Georgina; O'Toole, Sandra; Saw, Robyn; Scolyer, Richard; Smith, Elisabeth; Walker, Emily; Wilmott, James; Yu, Bing; Lum, Trina; Selinger, Christina; Central Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: Medicine; Medicine; Central Clinical School: Surgery; Central Clinical School: MedicineBRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting, Histopathology, vol.69, 4, 2016,pp 680-686
2013BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanomaHaydu, Lauren; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander; Scolyer, Richard; Thompson, John; Wilmott, James; Capper, D; Preusser, Matthias; von Diemling, Andreas Von; Zhang, Yuxiao; Central Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryBRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, British Journal of Cancer, vol.108, 4, 2013,pp 924-931
2016Brain Metastases from MelanomaHong, Angela; Long, Georgina; Thompson, John; Lyle, Megan; Shivalingam, Brindha; Central Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: SurgeryBrain Metastases from Melanoma in Brain Metastases from Primary Tumors, Volume 3: Epidemiology, Biology, and Therapy of Melanoma and Other Cancers, Academia Press, 2016, pp. 65-83